lmn-101
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04098263)
Timeline
Indications
Mechanism of action
- Campylobacter jejuniImmunity, passive
Campylobacter jejuni immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04182490 | Phase 2 | Feb 29, 2020 | Lumen Bioscience, Inc., Pharmaron, United States Navy, University of Maryland |
| NCT04098263 | Phase 1 | Jan 31, 2020 | Lumen Bioscience, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lumen Bioscience, Inc. | For profit | 2 | 2 | 2 | 2020 |
| Pharmaron | For profit | 1 | 0 | 1 | 2020 |
| United States Navy | Government | 1 | 0 | 1 | 2020 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1